<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087229</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-I/2008/AD-01</org_study_id>
    <secondary_id>2008-007161-23</secondary_id>
    <nct_id>NCT01087229</nct_id>
  </id_info>
  <brief_title>Effectiveness of an Oxygen-nitrous Oxide Mixture During Physical Therapy for Frozen Shoulder</brief_title>
  <acronym>MEOPA</acronym>
  <official_title>Comparative Study of the Effectiveness of an Equimolar Oxygen-nitrous Oxide Mixture During Physical Therapy for Adhesive Shoulder Capsulitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether or not the use of an equimolar mixture of&#xD;
      oxygen and nitrous oxide during the physical therapy for patients suffering from frozen&#xD;
      shoulder (adhesive shoulder capsulitis) results in a gain in shoulder amplitude (Constant&#xD;
      Score) and less pain as compared to patients undergoing physical therapy without this&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Constant Score using treatment as compared to without treatment.</measure>
    <time_frame>fifteen days of physical therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of passive glenohumeral flexion of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of passive glenohumeral abduction of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of passive glenohumeral external rotation (ER1) of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of active global anterior flexion of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of active global lateral flexion of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of active global abduction of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of active global external rotation (ER2) of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of active global internal rotation of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of passive global anterior flexion of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of passive global lateral flexion of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of passive global abduction of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kinetics at final session since baseline of passive global external rotation (ER2) of the shoulder</measure>
    <time_frame>Final session on Day 15</time_frame>
    <description>Range of motion in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at visits</measure>
    <time_frame>At each session: final session on Day 15</time_frame>
    <description>0-100 visual analogue scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain induced during sessions</measure>
    <time_frame>At each session: final session on Day 15</time_frame>
    <description>0-100 visual analogue scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement</measure>
    <time_frame>Day 7</time_frame>
    <description>Disabilities of the Arm Shoulder and Hand scale (DASH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement</measure>
    <time_frame>Day 15</time_frame>
    <description>Disabilities of the Arm Shoulder and Hand scale (DASH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement</measure>
    <time_frame>Day 45</time_frame>
    <description>Disabilities of the Arm Shoulder and Hand scale (DASH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement</measure>
    <time_frame>Day 180</time_frame>
    <description>Disabilities of the Arm Shoulder and Hand scale (DASH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limitations posed to the physiotherapist activity due to patient pain at each session</measure>
    <time_frame>At each session: final session on Day 15</time_frame>
    <description>Likert six-point scale (none, to extremely high)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>At each session: final session on Day 15</time_frame>
    <description>0-10 VAS: 10=session interrupted due to pain; 0= session completed under perfect conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Constant Score using treatment as compared to without treatment</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Constant Score using treatment as compared to without treatment</measure>
    <time_frame>Day 45</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Constant Score using treatment as compared to without treatment</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of life</measure>
    <time_frame>Day 1</time_frame>
    <description>Medical Outcome Study Short Form-36 (MOS-SF36) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of life</measure>
    <time_frame>Day 7</time_frame>
    <description>MOS-SF36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of life</measure>
    <time_frame>Day 15</time_frame>
    <description>MOS-SF36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of life</measure>
    <time_frame>Day 45</time_frame>
    <description>MOS-SF36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of life</measure>
    <time_frame>Day 180</time_frame>
    <description>MOS-SF36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antalgic intake</measure>
    <time_frame>Until end of study (Day 180)</time_frame>
    <description>Discriptively noted</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Adhesive Capsulitis</condition>
  <arm_group>
    <arm_group_label>equimolar oxygen-nitrous oxide mixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>equimolar oxygen-nitrous oxide mixture&#xD;
Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to this arm will have the placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>equimolar oxygen-nitrous oxide mixture</intervention_name>
    <description>Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.</description>
    <arm_group_label>equimolar oxygen-nitrous oxide mixture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Kinesitherapy is performed with a mask by which patient inhales a placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Affiliated with a social security system&#xD;
&#xD;
          -  Has signed the consent form&#xD;
&#xD;
          -  Patient has a painful, or initially painful but stable frozen shoulder (adhesive&#xD;
             capsulitis): stiffening characterized by a passive loss of amplitude on three planes.&#xD;
             This loss of amplitude is greater than or equal to 50% of controlateral amplitude when&#xD;
             the controlateral shoulder is considered as normal. Otherwise, the loss of amplitude&#xD;
             is greater than or equal to 50% of normal anatomical values.&#xD;
&#xD;
          -  Radiography confirms the integrity of the glenohumeral interspace.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intercurrent, evolving or unstable pathology: cancer, advanced cardio-vascular&#xD;
             pathology, severe infection&#xD;
&#xD;
          -  The patient is taking a treatment that may interfere with the study (eg corticoids,&#xD;
             pain killers, chemotherapy)&#xD;
&#xD;
          -  Contra-indication for physical therapy&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Advanced diabetes mellitus, with neurological or joint complications&#xD;
&#xD;
          -  Contra indication for the experimental treatment&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Patient's mental state prevents him/her from understanding the nature of the study,&#xD;
             its objectives and potential consequences.&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Patient is in an exclusion period determined by a previous study&#xD;
&#xD;
          -  Patient not able to follow protocol constraints or timetable&#xD;
&#xD;
          -  Medical history of local infection, polyarthritis or neuropathy that might explain the&#xD;
             shoulder pain.&#xD;
&#xD;
          -  Absence of radiculopathy of cervical origin, of rotator cuff tears or evolving&#xD;
             shoulder tendinopathy, of severe omarthrose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Dupeyron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité Rééducation Réadaptation Locomotrice</name>
      <address>
        <city>Le Grau du Roi</city>
        <state>Gard</state>
        <zip>30240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lapeyronie</name>
      <address>
        <city>Montpellier Cedex 05</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hélio Marin</name>
      <address>
        <city>Vallauris</city>
        <zip>06223</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

